1. Home
  2. SPRO vs DRCT Comparison

SPRO vs DRCT Comparison

Compare SPRO & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • DRCT
  • Stock Information
  • Founded
  • SPRO 2013
  • DRCT 2018
  • Country
  • SPRO United States
  • DRCT United States
  • Employees
  • SPRO N/A
  • DRCT N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • DRCT Computer Software: Programming Data Processing
  • Sector
  • SPRO Health Care
  • DRCT Technology
  • Exchange
  • SPRO Nasdaq
  • DRCT Nasdaq
  • Market Cap
  • SPRO 45.7M
  • DRCT 38.7M
  • IPO Year
  • SPRO 2017
  • DRCT 2022
  • Fundamental
  • Price
  • SPRO $0.83
  • DRCT $1.06
  • Analyst Decision
  • SPRO Buy
  • DRCT Strong Buy
  • Analyst Count
  • SPRO 4
  • DRCT 3
  • Target Price
  • SPRO $5.00
  • DRCT $21.00
  • AVG Volume (30 Days)
  • SPRO 217.5K
  • DRCT 264.0K
  • Earning Date
  • SPRO 03-12-2025
  • DRCT 03-20-2025
  • Dividend Yield
  • SPRO N/A
  • DRCT N/A
  • EPS Growth
  • SPRO N/A
  • DRCT N/A
  • EPS
  • SPRO 0.06
  • DRCT N/A
  • Revenue
  • SPRO $106,455,000.00
  • DRCT $94,216,000.00
  • Revenue This Year
  • SPRO N/A
  • DRCT N/A
  • Revenue Next Year
  • SPRO N/A
  • DRCT $37.23
  • P/E Ratio
  • SPRO $12.71
  • DRCT N/A
  • Revenue Growth
  • SPRO 37.01
  • DRCT N/A
  • 52 Week Low
  • SPRO $0.74
  • DRCT $0.51
  • 52 Week High
  • SPRO $1.89
  • DRCT $35.88
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 44.07
  • DRCT 41.45
  • Support Level
  • SPRO $0.82
  • DRCT $1.10
  • Resistance Level
  • SPRO $0.85
  • DRCT $1.18
  • Average True Range (ATR)
  • SPRO 0.05
  • DRCT 0.08
  • MACD
  • SPRO 0.01
  • DRCT 0.01
  • Stochastic Oscillator
  • SPRO 43.33
  • DRCT 10.00

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

Share on Social Networks: